日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system

双重免疫检查点抑制剂相关的心脏不良事件:来自FDA不良事件报告系统的药物警戒分析

Xia, Huang; Shi, Lei; Luo, Shuimei; Sun, Zequn; Quan, Mengru; Xiao, Huazhen; Chen, Yu; Lin, Jing

Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer

综合分析揭示PTK6是乳腺癌免疫抑制微环境中的预后生物标志物

Wang, Lili; Luo, Shuimei; Wang, Ziming; Huang, Yiqiang; Luo, Yang; Xie, Xianhe

The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

抗肿瘤疗法对合并 COVID-19 的癌症患者预后的影响:一项基于 52 个队列、共纳入 9231 名参与者的荟萃分析

Wu, Qing; Luo, Shuimei; Xie, Xianhe

Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

淋巴细胞与单核细胞比值(LMR)在接受免疫检查点抑制剂治疗的癌症患者中的预后价值

Wan, Luying; Wu, Chunlan; Luo, Shuimei; Xie, Xianhe

Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer

EGFR突变状态与非小细胞肺癌患者脑转移发生率的相关性

Li, Lina; Luo, Shuimei; Lin, Heng; Yang, Haitao; Chen, Huijuan; Liao, Ziyuan; Lin, Wanzun; Zheng, Weili; Xie, Xianhe

A Comprehensive Model for Predicting Recurrence and Survival in Cases of Chinese Postoperative Invasive Breast Cancer

中国术后浸润性乳腺癌复发及生存预测的综合模型

Xie, Xianhe; Hu, Yanfen; Jing, Chao; Luo, Shuimei; Lv, Yunfu; Yang, Haitao; Li, Lina; Chen, Huijuan; Lin, Wanzun; Zheng, Weili

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

血管生成抑制剂在小细胞肺癌中的疗效和安全性

Lin, Heng; Li, Lina; Luo, Shuimei; Zhou, Sijing; Shen, Ruifen; Yang, Haitao; Chen, Huijuan; Xie, Xianhe

Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials

低剂量与常规剂量化疗治疗恶性肿瘤的疗效和毒性:6项随机对照试验的荟萃分析

Xie, Xianhe; Wu, Yupeng; Luo, Shuimei; Yang, Haitao; Li, Lina; Zhou, Sijing; Shen, Ruifen; Lin, Heng

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.

非小细胞肺癌中程序性死亡配体 1 表达与驱动基因突变的相关性

Yang Haitao, Chen Huijuan, Luo Shuimei, Li Lina, Zhou Sijing, Shen Ruifen, Lin Heng, Xie Xianhe

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

评估酪氨酸激酶抑制剂联合放射疗法治疗非小细胞肺癌脑转移患者的疗效和安全性

Luo, Shuimei; Chen, Long; Chen, Xiuping; Xie, Xianhe